The DOI matches its Crossref record; 4 of the 5 references it cites were found in a registry or an index.
ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Open accessAbstract
Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several novel therapies that potently reduce triglyceride levels are currently in development.[6][7][8]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [7]
In the citing paper
“It is of particular interest that, contrary to other lipid-lowering drugs, such as PCSK9 inhibitors,21,22 the lipid lowering effect of ANGPTL3 inhibition by evinacumab seems to be independent of the presence of residual LDLR activity, supporting the data obtained in animal models,6,10 as well as in a pilot clinical trial.9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Based on the data collected during the parent clinical trials and other studies, LDL-C levels typically reach nadir after 4 weeks of receiving evinacumab infusion and remain generally stable at week 6.9”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationGenetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationExome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
“In patients with homozygous familial hypercholesterinaemia, evinocumab could reduce the level of plasma LDL from 20% to 90% and TG ~50%.(291) On the other hand, ANGPTL3-specific antisense oligonucleotides (ASOs) could inhibit ANGPTL3 synthesis.”
BackgroundEvinacumab for Homozygous Familial Hypercholesterolemia
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793
Self-citationFerence, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703
Metadata
- Authors
- Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., Khoury, E., Banerjee, P., Gusarova, V., Gromada, J., Stahl, N., Yancopoulos, G. D., & Hovingh, G. K.
- Affiliations
- Université de Montréal (CA)
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pennsylvania (US)
- Cedars-Sinai Medical Center (US)
- University of Amsterdam (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-20
- Volume
- 377
- Issue
- 3
- Pages
- 296-297
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2738009647
- Cited by
- 323
- References
- 5
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 29 · 2023: 23 · 2022: 41 · 2021: 58 · 2020: 62 · 2019: 36 · 2018: 30 · 2017: 4
- FWCI
- 36.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, evinacumab, homozygous familial hypercholesterolemia, LDL cholesterol lowering, monoclonal antibodies, cholesterol absorption inhibition, lipid-lowering therapy
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Antibodies, Monoclonal, Genotype, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Receptors, LDL, Angiopoietins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. https://app.cochat.ai/papers/10.1056/nejmc1705994
- The paper
- Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., Khoury, E., Banerjee, P., Gusarova, V., Gromada, J., Stahl, N., Yancopoulos, G. D., & Hovingh, G. K. (2017). ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. New England Journal of Medicine. https://doi.org/10.1056/nejmc1705994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.